申请人:Haptogen Ltd
公开号:EP2261260A2
公开(公告)日:2010-12-15
The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.
本发明涉及通过调节细菌细胞信号分子的细胞外浓度来杀死传染性细菌的方法。其效果是诱导大多数细菌细胞快速死亡(自溶),防止毒力增强或使存活细胞恢复良性状态。这些受体可用于治疗易受感染的个体、治疗已有感染的病人、疾病管理以及感染宿主为动物或植物的相关应用。本文所述组合物尤其适用于铜绿假单胞菌感染,例如用于治疗囊性纤维化患者的肺部感染,是一种不直接针对细菌的独特杀菌药物。